Vivosim Labs, Inc. · NASDAQ:VIVS

Vivosim Labs — Investor Presentation (2026)

22 slides from Vivosim Labs's investor presentation, 2026

Slide 1: Liver and Intestinal Toxicology Model Innovation
Liver and Intestinal Toxicology Model Innovation NAMkind contract research for pharma of all sizes © Copyright 2025 VivoSim, Inc. NASDAQ: VIVS 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or in other documents of Organovo Holdings, Inc. (the “Company” or “Organovo”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, ar
Slide 3: Investment Highlights
Investment Highlights • We create the most predictive non-animal models (NAMs), 3d models of human tissues • We test Pharma’s drugs for problems as a CRO high value service, -Liver toxicity and intestinal side effects like diarrhea • We save Pharma major dollars on their failures - $50-$200M before
Slide 4: Competitive Landscape
Competitive Landscape Top Tier Low Cost Intestine side effects Detection InSphero + - n/a Emulate - + n/a VivoSim + + Launching model VivoSim offers the best combination of high-quality data and price point in the market © Copyright 2025 VivoSim, Inc. NASDAQ: VIVS 4
Slide 5: Value Proposition to Pharma
Value Proposition to Pharma Costs of Drug Development for $340M Typical Program Risk-Adjusted Failure Cost $79M Liver Tox Failure Rate 5% What we Per Program Liver Tox Expected save Pharma $3.7M Value Cost What we VivoSim Liver Services to Remove charge $25k-$50k Pharma 50-80% of risk of liver failu
Slide 6: NAMKind - Intersection of Key Advantages
NAMKind - Intersection of Key Advantages Human Cell Culture Useful for molecular insights True biology NAMKind models unite key advantages: • Human relevance • 3D complexity • Controlled experiments Gold standard for Medium throughput w/ deep analytical human relevance Controlled High cost and 3D Cu
Slide 7: Sample Customer Use Cases in Drug Development
Sample Customer Use Cases in Drug Development Useful for molecular insights Oversimplified biology Lead Candidate Hit to Lead IND-Enabling Clinical Trials Optimization Nomination Prospective Toxicity Translational Risk Investigational Screens Bridge Toxicology Screen De-risk finalists Use NAMkind mo
Slide 8: Maximizing Uptake Potential
Maximizing Uptake Potential • VivoSim will customize service solutions to serve client needs • Fee For Service • Screening and candidate prioritization • Pricing per compound per assay • FTE models available for in depth work- investigational toxicology and bespoke assays • Research Collaborations •
Slide 10: NAMkind Liver for DILI Predictive Testing
NAMkind Liver for DILI Predictive Testing Donor Liver Tissue Isolate, expand, and freeze high quality cells Proprietary multicellular 3D models in 96-well plates for drug testing Hepatocyte Stellate cell Kupffer cell Endothelial cell © Copyright 2025 VivoSim, Inc. NASDAQ: VIVS 10
Slide 11: 3D Liver Models Offer Additional Insight Into Liver Function
3D Liver Models Offer Additional Insight Into Liver Function Model Prediction Accuracy 92% overall detection Selectivity 88% detect true problem False positive rate 0% predict problem falsely • We find 87.5%+ of difficult to see liver toxicity issues, many of which are missed by animal models and tr
Slide 12: 3D Liver Spheroids Accurately Predict Differential Toxicity
3D Liver Spheroids Accurately Predict Differential Toxicity Between Structurally Similar Compounds Troglitazone: caused severe drug induced liver injury and deaths, pulled from market. CTG Cell Titer Our model shows it kills liver cell function, and it would never have been developed with Glo these
Slide 14: NAMkind GI for Predictive Testing
NAMkind GI for Predictive Testing Accurate Intestinal Structure With Intact Epithelium • Tissue consists of human primary epithelial, smooth muscle, fibroblast, and endothelial cells, from healthy donors. Alcian Blue (mucin) • Physiological barrier function: • Polarized epithelium. • Tight junctions
Slide 15: Validation of GI Model
Validation of GI Model Previous Version DIARRHEAGENIC SAFE 4-ASA Alosetron 5-Fluorouracil Busulfan Model Prediction Afatinib Celecoxib Azathioprine Dexamethasone Belumosudil Bortezumib Finasteride Glafenine Accuracy 96% overall detection Bosutinib Isoprenaline Carboplatin Loperamide Crizotinib Metho
Slide 16: Differential Diarrhea Causation of Anti-Inflammatory Drugs Is Seen in Intestine Models
Differential Diarrhea Causation of Anti- Inflammatory Drugs Is Seen in Intestine Models Diclofenac Indomethacin Etericoxib Celecoxib Severe Diarrhea Moderate Mild The relative polygon areas in radar plots highlight differences between diarrheagenic drugs and their safer structural analogs. Four (4)
Slide 18: ADCs toxic in human liver also toxic in NAMkind Liver
Antibody-Drug Conjugagtes (ADCs) toxic in human liver also show as clearly toxic in NAMkind Liver Gemtuzumab Ozogomycin ATP Trastuzumab Deruxtecan ✱✱✱✱ 150 ✱✱✱✱ ✱✱✱✱ 150 IgG ✱ Normalized Values ADC Normalized RLU (mean ± SD) 100 (mean ± SD) 100 50 50 0 .5x 1x 20x .5x 1x 20x 0 0 0 ATP Albumin LDH IgG
Slide 19: ADC testing opportunity
ADC testing opportunity • 65% of Oncology pipelines have one or more ADCs • Fast growing modality, with almost 20 ADCs approved in recent years • Limited by non-specific toxicity (liver etc) • Benefit tremendously from counter-screening in VivoSim models • We are developing solutions for all drug ty
Slide 21: FDA initiative: Phasing Out Animal Testing
We benefit from a strong rising tide, the FDA initiative: Phasing Out Animal Testing FDA’s New Approach announced April 2024 Launching a plan to modernize drug development practices. Focused on reducing and replacing animal testing requirements. Goals of the Initiative Improve drug safety and predic

VivoSim Labs — Investor Presentation (2026) on 6ix

Vivosim Labs — Investor Presentation (2026)

Slide 1: Liver and Intestinal Toxicology Model Innovation

Slide 2: Forward Looking Statements

Slide 3: Investment Highlights

Slide 4: Competitive Landscape

Slide 5: Value Proposition to Pharma

Slide 6: NAMKind - Intersection of Key Advantages

Slide 7: Sample Customer Use Cases in Drug Development

Slide 8: Maximizing Uptake Potential

Slide 9: VivoSim Liver Tox Model

Slide 10: NAMkind Liver for DILI Predictive Testing

Slide 11: 3D Liver Models Offer Additional Insight Into Liver Function

Slide 12: 3D Liver Spheroids Accurately Predict Differential Toxicity

Slide 13: VivoSim Intestinal Model

Slide 14: NAMkind GI for Predictive Testing

Slide 15: Validation of GI Model

Slide 16: Differential Diarrhea Causation of Anti-Inflammatory Drugs Is Seen in Intestine Models

Slide 17: Antibody Drug Conjugates

Slide 18: ADCs toxic in human liver also toxic in NAMkind Liver

Slide 19: ADC testing opportunity

Slide 20: FDA NAMs Initiative

Slide 21: FDA initiative: Phasing Out Animal Testing

Slide 22: Contact Details